Driving Business Compliance with IT Processes
This article was originally published in SRA
Business compliance is becoming an increasingly important requirement for the pharmaceutical industry. Drug companies are becoming subject to a growing number of regulations both in the European Union and US as part of efforts by governments, regulators and industry itself to prevent fraud, unfair competition, unscrupulous advertising and marketing practices and inappropriate interactions with healthcare professionals.
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.